NFA
RNAC icon

Nationwide Fund Advisors’s Cartesian Therapeutics RNAC Stock Holding History

Nationwide Fund Advisors’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-250
Closed -$137K – 1666
2017
Q3 		$137K Buy
250
+30
+14% +$16K ﹤0.01% 2781
2017
Q2 		$131K Buy
220
+152
+224% +$67.1K ﹤0.01% 2791
2017
Q1 		$29K Buy
+68
New +$28.6K ﹤0.01% 3057

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nationwide Fund Advisors's RNAC Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Cartesian Therapeutics (RNAC) in Q4 2017, closing a stake of 250 shares — an estimated $137K sold.

Nationwide Fund Advisors first reported a position in RNAC in Q1 2017 and held it in 3 quarters. The position peaked at $137K in Q3 2017. 63 funds tracked by Wall St. Rank hold RNAC as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Cartesian Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 250 Cartesian Therapeutics shares in Q4 2017, an estimated $137K.
  • Nationwide Fund Advisors first reported a position in Cartesian Therapeutics in Q1 2017 and held it in 3 quarters.
  • Nationwide Fund Advisors's Cartesian Therapeutics position peaked at $137K in Q3 2017.
  • 63 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.